We are building a future where biology is solvable
The path to new medicines is currently slow and expensive with high failure rates, leaving millions of patients waiting for new treatment options.
Our story is one of innovation: applying AI, vast datasets, and industrial scale to decode biology and accelerate the development of life-changing treatments.
Our mindset
Our mindset is guided by an unwavering drive to challenge and disrupt the status quo. We diligently guard against complacency, conservatism, risk aversion, and contentment with the familiar. We are not here to make a few medicines. We are here to reimagine how medicines are made.
The Recursion mindset is the deep belief and commitment to industrializing drug discovery through automation, algorithms, and data to deliver on our mission. This is supported by our culture and values.
Recursion Decoded
Recursion Decoded tells the story of a new kind of TechBio company. One that values big swings over cautious steps. One where the “bilingual” workforce of “Recursionauts” is made up of a nearly equal balance of technologists and life scientists. And one where we won’t be satisfied with incremental improvements to the status quo. Read about how we are building the TechBio company of the future.
Timeline
November 5, 2013
Recursion is founded
October 5, 2015
First FDA Orphan Drug designation received for a clinical program
September 2, 2016
Close Series A financing with lead investor Lux Capital
September 25, 2017
Close Series B financing with lead investor DCVC
July 10, 2018
First IND granted for an in-licensed molecule, to initiate Recursion’s first clinical trial
May 6, 2019
Release first open-source data; launch RxRX1 machine learning competition on Kaggle
September 9, 2020
June 15, 2021
First FDA Fast Track Designation received
March 11, 2024
November 12, 2024
2013
November 5, 2013
Recursion is founded
2015
October 5, 2015
First FDA Orphan Drug designation received for a clinical program
2016
September 2, 2016
Close Series A financing with lead investor Lux Capital
2017
September 25, 2017
Close Series B financing with lead investor DCVC
2018
July 10, 2018
First IND granted for an in-licensed molecule, to initiate Recursion’s first clinical trial
2019
February 12, 2019
Close the Series C financing with new, lead investor Baillie Gifford
May 6, 2019
Release first open-source data; launch RxRX1 machine learning competition on Kaggle
2020
April 24, 2020
Release second open-source data; launch RxRX19 & RxRx2 on SARS-CoV-2 virus
September 9, 2020
2021
June 15, 2021
June 15, 2021
First FDA Fast Track Designation received
2022
2023
2024
March 11, 2024
March 13, 2024
Completion of NVIDIA-powered BioHive-2, the largest supercomputer in the pharmaceutical industry
October 2, 2024
November 12, 2024
Help us explore the uncharted
Explore careers
© 2025 Recursion. All rights reserved.
